Alcon, the global number one in eye care, reported second-quarter 2026 net sales of $2.8 billion on August 10, up 8 percent on a reported basis and 7 percent on a constant currency basis, which strips out currency swings, from the same quarter a year ago. The headline diluted earnings per share of $0.00 looks alarming, but the entire gap between that print and the health of the underlying business sits in a single non-cash accounting charge. Alcon decided to discontinue the intraocular lens programs acquired from PowerVision in 2019 after a subset of patients experienced unpredictable post-surgical visual outcomes that multiple development efforts could not fix, and this decision forced a $402 million pre-tax write-down in the quarter, or about $287 million after tax.
What the market is missing, in our view, is that this charge has nothing to do with how the franchise is operating. Strip out the write-down, along with amortization and other one-time items, and Alcon's core operating income, its profit before these non-cash and non-recurring charges, rose 17 percent to $574 million, with the core operating margin expanding 1.5 percentage points to 20.6 percent. Core diluted earnings per share, the measure management uses to track the underlying business, climbed 11 percent to $0.84. The growth is broad-based rather than dependent on any single product, with both the Surgical and Vision Care segments expanding, and management raised the full-year 2026 forecast for core operating margin and core earnings per share even as it kept the revenue outlook unchanged. The PowerVision charge does not touch cash and does not alter Alcon's long-range financial targets.
The single load-bearing risk is that the equity has de-rated roughly a quarter from its 52-week high of $90.41, closing at $74.25, and the market appears to be pricing in a peak in growth for a company whose raised guidance implies the opposite. The falsifiable clock is the next earnings report, covering the third quarter of 2026, when investors see whether the double-digit core earnings growth, the $60 million tariff refund expected in the third quarter, and continued share gains in contact lenses show up in the numbers. If the third quarter confirms core operating margin expansion at or above the raised guidance band, the current de-rating looks like a mispriced entry window; if growth snaps back toward the low single digits, the market's caution deserves to stand.